HUTCHMED (China) Ltd (HCM) stock
Close on Nov 17, 2026Market cap $2.51BP/E 5.5Yield –
Earnings
HUTCHMED (China)'s quarterly results as reported in its earnings releases, with the company's own outlook. Hover a number to see the sentence it came from.
Quarterly results
Revenue and earnings per share from each of HUTCHMED (China)'s earnings releases, newest first
| Quarter | Reported | Revenue | YoY | EPS | Source |
|---|---|---|---|---|---|
| Q2 FY2026ended Jun 30, 2026 | Jul 30, 2026before the open | – | – | – | Release |
| Q4 FY2025ended Dec 31, 2025 | Mar 5, 2026before the open | – | – | – | Release |
| Q2 FY2025ended Jun 30, 2025 | Aug 7, 2025before the open | – | – | – | Release |
| Q4 FY2024ended Dec 31, 2024 | Mar 19, 2025before the open | – | – | – | Release |
| Q2 FY2024ended Jun 30, 2024 | Jul 31, 2024before the open | – | – | – | Release |
| Q4 FY2023ended Dec 31, 2023 | Feb 28, 2024before the open | – | – | – | Release |
| Q2 FY2023ended Jun 30, 2023 | Jul 31, 2023before the open | – | – | – | Release |
| Q4 FY2022ended Dec 31, 2022 | Feb 28, 2023before the open | – | – | – | Release |
| Q2 FY2022ended Jun 30, 2022 | Aug 1, 2022before the open | – | – | – | Release |
| Q4 FY2021ended Dec 31, 2021 | Mar 3, 2022before the open | – | – | – | Release |
Figures as first announced; later restatements appear under Financials. Expected dates are estimated from the company's past reporting pattern.
Current guidance
HUTCHMED (China)'s latest outlook for periods it has not reported yet, compared with what it said before
| Metric | Period | Guidance | Before | Change | Given |
|---|---|---|---|---|---|
| Oncology/Immunology consolidated revenue | FY2026 | $330.00M – $450.00M | $330.00M – $450.00M | Reaffirmed | Jul 30, 2026 |
Guidance history
Every forecast HUTCHMED (China) put in an earnings release, newest first
| Given | Metric | Period | Guidance | Change |
|---|---|---|---|---|
| Jul 30, 2026 | Oncology/Immunology consolidated revenue | FY2026 | $330.00M – $450.00M | Reaffirmed |
| Mar 5, 2026 | Oncology/Immunology consolidated revenue | FY2026 | $330.00M – $450.00M | New |
| Aug 7, 2025 | Oncology/Immunology consolidated revenue | FY2025 | $270.00M – $350.00M | Lowered |
| Mar 19, 2025 | Oncology/Immunology consolidated revenue | FY2025 | $350.00M – $450.00M | New |
| Jul 31, 2024 | growth target in oncology marketed product revenue | FY2024 | +30% – +50% | New |
| Jul 31, 2024 | Oncology/Immunology consolidated revenue | FY2024 | $300.00M – $400.00M | Reaffirmed |
| Feb 28, 2024 | Oncology/Immunology consolidated revenue | FY2024 | $300.00M – $400.00M | New |
Read from the company's earnings releases; each figure links to its sentence on hover. “Raised” and “Lowered” compare with the previous range for the same metric and period.
Press releases
Releases HUTCHMED (China) filed with the SEC as exhibits to Form 8-K or 6-K
- 6-K
- 6-K
- 6-K
- 6-K
- 6-K
- 6-K
- 6-K
- 6-K
- 6-K
- 6-K
- 6-K
- 6-K
- 6-K
- 6-K
- 6-K
See a number that looks wrong?